1 softgel contains:
- 50mg
- Green-Lipped Mussel fatty acid extract (Perna canaliculus)
Other Ingredients:
Olive Oil, D-alpha Tocopherol (from soy). Capsule: Gelatin (bovine), Glycerin.
Olive Oil, D-alpha Tocopherol (from soy). Capsule: Gelatin (bovine), Glycerin.
Format
Softgels
60 Softgels
Dosage
Take two softgels twice daily for the first two months, followed by one softgel twice daily for the next four months, take with a fat-containing meal, or as directed by a qualified health care practitioner.
Important Information
Contains no wheat, gluten, corn, nuts, peanuts, sesame seeds, sulphites, mustard, dairy or eggs. Consult a health care practitioner for use beyond six months or if symptoms persist or worsen. Do not use if pregnant or breastfeeding. This product contains soy and shellfish derived ingredients, do not use if you have such allergies.
Highlights
- Support against inflammation.
- Rheumatoid or Osteo arthritis support.
- MS, PMS & asthma support.
- Alternative to fish oils.
- Easy to swallow.
Related Videos
No Related VideosArticles by a naturopathic doctor.
Manufacturer Info
AOR Canada is the innovative formulators of Canada’s best-selling antioxidant support, AOR Advanced B Complex and AOR Tri-B12. They are also known for their top bone health supplements, Ortho Adapt and Bone Basics. You can also SHOP AOR's Nattokinase, and trusted Curcumin Ultra, Curcumin Active and Curcumin95 inflammation support at National Nutrition.ca. AOR are leaders in natural health with innovative product development.
Omega-3 fatty acids are now well-known inflammation fighters. Controlled clinical trials clearly show that they fight inflammation, reducing and in some cases eliminating the need for anti-inflammatory drugs with their disturbing short- and long-term side effects. Both omega-3 fatty acids, and nearly all anti- inflammatory drugs, work through their effects on a group of local, cellular "hormones" called eicosanoids.
Eicosanoids are messengers that cells use to communicate with one another, coordinating their activities. Some ("bad") eicosanoids promote inflammation, while other ("good") eicosanoids have potent anti-inflammatory functions. Thus, the body's inflammatory response rests in large part on the balance of "good" and "bad" eicosanoids produced by your cells when they hear the immune system's inflammatory call.
"Bad" eicosanoids are made from an omega-6 fatty acid called arachidonic acid. Most drug approaches to inflammation, from aspirin and the older NSAIDs (Non-Steroidal Anti-Inflammatory Drugs, like ibuprofen) to the new "COX-2 inhibitor" drugs, like celecoxib [Celebrex] and rofecoxib [Vioxx]), work by inhibiting the formation of the series-2 prostanoid group of "bad" eicosanoids. Prostanoids are formed from arachidonic acid by an enzyme called cyclooxygenase, or COX. (AA).
But while these drugs certainly provide symptomatic relief in the short term, COX-2 inhibitors can actually accelerate the underlying inflammatory disease in the long term, by diverting arachidonic acid into another, slower-acting, and ultimately more destructive pathway: the lipoxygenase (LOX) enzyme pathway, which produces the ravaging series-4 leukotrienes. Leukotrienes are the eicosanoids released by immune cells involved in the body's inflammatory responses, and are more responsible for the long-term consequences of inflammation, which can result when a deranged immune system attacks the very body that it was designed to defend.
Therefore, blocking the COX pathway alone results in an imbalance - an imbalance that ultimately trades short-term gain for long-term pain. What people suffering with autoimmune disorders most need is a "dual pathway inhibitor:" a molecule which will shut down COX-2 and LOX alike, preventing the formation of all "bad" eicosanoids.
Transnational pharmaceutical giants are racing to create such drugs. But Nature is already waiting for them at the finish line, with two rare omega-3 fatty acids.
Introducing ETA and SDA
Eicosatetraenoic acid (ETA) and its raw material stearidonic acid (SDA), are omega-3 fatty acids you probably haven't heard much about. Because ETA and SDA are so rare in food sources, there's been little study of their role in the effects of diet on chronic disease (unlike eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which are commonly found in fatty fish and in regular fish-oil supplements).
While ETA is very rare in the normal Western diet, it is found in significant amounts in the fatty acids of the green-lipped mussel (Perna canaliculus). Many early studies in humans and animals found that crude extracts of Perna were effective in reducing inflammation, and in relieving the symptoms of rheumatoid and osteoarthritis - but other studies found no effect.
The reason, as later studies confirmed, was that the anti-inflammatory properties of the green-lipped mussel were due to their content of SDA and ETA. Most green-lipped mussel supplements are not stable fatty acid extracts, but are crude concentrates or are based on mucopolysaccharides. When seven commercially-available green mussel products were put to the test by comparing them with a stable fatty extract rich in ETA and SDA, the fatty acid extract revealed strong anti-inflammatory powers, while the other extracts were found to vary wildly in strength. Great variations were even revealed in different batches of the same product.
More tellingly, when the inflammation-fighting powers of a stable ETA- and SDA-rich extract were compared with crude P. canaliculus extracts whose fatty acid content had been deliberately removed, the fatty acid extract of the mussel exhibited potent anti-inflammatory effects, while the ETA-depleted preparation was found to be completely ineffective.
ETA and SDA Top the Omega-3s
Two direct comparison studies have been performed in animals to compare the anti-inflammatory effects of the ETA- and SDA-rich oil of P. canaliculus against those of salmon, cod liver, flaxseed, and two mixed fish oils. These studies clearly show that the ETA- and SDA-rich fatty acid extract of P. canaliculus is far superior to other omega-3 sources at quenching the fires of inflammation, giving more potent anti-inflammatory benefits at significantly lower doses.
Using the series of tests discussed above, ETA/SDA supplementation lowered arthritis scores by 4213% to 7515%, versus 0 to 31% using conventional omega-3 sources. Likewise, rear paw swelling was reduced by 96-98% by the ETA/SDA-rich oil, while swelling was only lowered by 7 to 38% with common omega-3s! These results are all the more remarkable because the dose of ETA/SDA-rich P. canaliculus oil was only about 1% of that used for the standard omega-3 oils.
Another recent study tested the effects of these novel fatty acids in a rat model of arthritis. After 15 days of administering omega-3 fatty acid extracts from P. canaliculus, rear paw swelling was significantly reduced by 34% and fore paw inflammation by 60%. Deterioration in total body condition was reduced by 52% compared to controls. The extract also decreased inflammatory response in the spleen, and it had a 35-70% inhibition of leukotriene metabolites. Serum levels of the inflammatory biomarker ceruloplasmin were reduced compared to control mice, indicating a less severe disease state. Interestingly, the fatty acids had comparable potency to the known anti-inflammatory agent piroxicam. The fatty acid extract had no adverse side effects. These results suggest a potential benefit not only in rheumatoid arthritis, but also in other inflammatory diseases such as psoriasis, asthma and cardiovascular disease.
A New Human Trial
In a new randomized, double-blind, controlled trial involving rheumatoid and osteoarthritis sufferers, significant improvements were reported in morning stiffness and measures of joint functionality during the double-blinded phase among rheumatoid arthritis sufferers taking the SDA/ETA-rich oil; further, night pain was "much improved" in 40% of subjects, and vanished in an additional 26.7%. Improvements were also seen in some patients' grip strength and overall visual-scale pain scores, but these results were not found statistically meaningful. Assessment by doctors and patients concluded that 73% of the persons with rheumatoid arthritis had experienced a good response - including 20% who became completely symptom-free by the end of the double-blind phase. The results were similar in the osteoarthritis victims.
Similar results have been reported in an unpublished pilot trial and in case reports. A double-blind, placebo-controlled trial vouches for the benefits of an SDA- and ETA-rich fatty acid supplement in bronchial asthma, and testimonial accounts and animal studies suggest benefits in premenstrual syndrome as well.
An Impressive Track Record
The accumulation of clinical and other scientific evidence pertaining to the efficacy and safety of ETA/SDA-rich oil has been growing steadily. The following is a partial summary of such studies:
1.Whitehouse Study 1. Anti-inflammatory activity of Lyprinol. Inflammapharmacology. 1997. Lyprinol was compared with dried mussel powder, residue mussel powder, Aspirin, Ibuprofen and Naproxen using the Wister rat protocol. Lyprinol was shown to be far superior as an anti-inflammatory.
2.Whitehouse Study 2. OTC oral remedies for arthritis. Lyprinol was compared to a multitude of over-the-counter products using the Wister rat protocol and was again shown to be a potent natural anti-inflammatory.
3.Sheila Gibson Study - Treatment of arthritis with Lyprinol. Complementary Therapies in Medicine (1998). This trial involved 60 patients, 30 osteoarthritis patients and 30 rheumatoid arthritis patients, during a period of three months. Lyprinol was compared to green-lipped mussel powder and was shown to outperform green-lipped mussel powder quite significantly.
4.Niels Hertz Study - Pilot study 13 patients 1998. This small pilot trial was conducted on 13 patients who had osteoarthritis. Within three to four months 12 of the 13 patients reported a 50 per cent reduction in arthritisrelated pain.
5.The effect of marine oils on markers of thrombosis in the blood of healthy females. Steve Hooper - October 1998. This trial involved 10 female subjects who took two different omega-3 products. One was Lyprinol and the other was a fish oil called Fishaphos. Both products showed no significant effect on any of the antithrombotic parameters measured.
6.Marine lipids: overview, new insights and lipids composition of Lyprinol. Andrew J. Sinclair, Karen J. Murphy and Li - Department of Food Science, RMIT University. This paper outlines the differences between the composition of Lyprinol compared with other oils that contain omega-3s.
7.Shiela L. M. Gibson - The effect of a lipid extract of the New Zealand greenlipped mussel in three cases of arthritis. The Journal of Alternative and Complementary Medicine, volume 6, number 4, 2000. In this trial, three cases of rheumatoid arthritis were looked at and treated with Lyprinol. In all three cases, the patients reported reduced pain, reduced stiffness and swelling, along with improved grip strength.
8.Chris D. Meletis, N. D. - Natural relief for inflammation of sprains, strains and arthritis. Alternative and Complementary Therapies - June 2000. This small comparison study outlined that Lyprinol with a dosage of 100mg twice daily is very effective in the management of sprains and strains.
9.Allergies and Immunologies no. 7 - September 2000 G. M. Halpern A. N. Naykhin, R. Borland, L. G. Rudenko (abstract) Lyprinol - a new modulator of human immune response to viral antigen. This report establishes the safety and effectiveness of Lyprinol by referring to many of the clinical trials that have been performed on Lyprinol.
10.A. N. Naykhin, R. Borland, G. G. Rudenko (paper) - Immunomodulating effect of Lyprinol in humans vaccinated with live influenza vaccine. This clinical trial indicated that Lyprinol possessed rather powerful immunomodulating properties (likely to have prolonged action) by enhancement of specific systemic and partly local and cellular immunity stimulation.
11.Dr M. W. Whitehouse et al (1997) Inflammopharmacology, 5.237-246 (Proceedings of ASCEPT) - The marine oil Lyprinol is a substrate for the 5-lipoxygenase enzyme in porcine neutrophils. - Steriod-sparing action of Lyprinol, a lipid fraction from the New Zealand greenlipped mussel.
12.English version of the Korean: Multicentre clinical trial of Lyprinol - published in 'The Newest Medical Journal (Korea) 2002 5.6 ISSN 0529-3804 (pages 27-33)'. This study was conducted in Korea on 54 patients who suffered from osteoarthritis. Eighty per cent displayed significant pain relief and joint mobility after eight weeks.
13.A. Emelyanov, G. Fedoseev, O. Krasnoschekova, A. Abulimity, T. Trendeleva, P. J. Barnes - Treatment of asthma with lipid extract of New Zealand green-lipped mussel: a randomized clinical trial. The Emelyanov study consisted of 40 mild, steroid naive asthmatics who received either an active or placebo dosage of 100mg per day. After 56 days, the patients in the active group showed a positive effect on clinical symptoms.
14.Gastroprotective and anti-inflammatory properties of green-lipped mussel (Perna canaliculus) preparation - By K. D. Rainsford and M. W. Whitehouse Arzneim-Forsch./Drug Res. 30(II), Nr.12 (1980). This small animal study indicated that this material reduced the gastric ulcerogenicity of several non-steroid anti-inflammatory drugs in rats and pigs.
15.Programme and abstracts annual scientific meeting, November 30 - December 3, 2003, Sydney. Australian Society of Clinical and Experimental Pharmacologists and Toxicologists, Vol. 10, 2003. Lyprinol effects on allergen-induced esinophil infiltration into the airways of sensitised guinea pigs in vivo.
16.Professor C. S. Lau. Volume number 6, N. 1/2004, pages. 17-31) Progress in Nutrition 2004. Treatment of knee osteoarthritis with Lyprinol, lipid extract of the green-lipped mussel, a double-blind placebo-controlled study. This study was conducted on 80 osteoarthritis sufferers and concluded that Lyprinol, a lipid extract of the green-lipped mussel, be considered a safe option in the treatment of osteoarthritis.
17.M. W. Whitehouse and D. E. Butters article in the Inflammopharmacology, volume 11, 4-6, pages 453-464 (2003) Combination anti-inflammatory therapy: synergism in rats of NSAIDs/corticosteroids with some herbal/animal products.
18.M. W. Whitehouse - Inflammopharmacology, Vol. 12, No. 3, pp. 223 - 227 (2004) Anti-TNF-alpha therapy for chronic inflammation: reconsidering pentoxifylline as an alternative to therapeutic protein drugs. Professor Whitehouse outlines in this paper that Lyprinol and pentoxifylline work extremely well together as a combination anti-inflammatory.
19.Joerg Gruenwald, Hans-Joachim Graubaum, Knuth Hansen, Barbara Grube - Advances In Natural Therapy, volume 21, number 3 May/June 2004 Efficacy and tolerability of a combination of Lyprinol and high concentrations of EPA and DHA in inflammatory rheumatoid disorders. This 12-week drug monitoring study evaluated the effects of Lyprinol omega-3 complex on 50 adult men and women suffering from inflammatory rheumatoid arthritis. Thirty-four of the 50 patients required medical treatment before and during the study. Upon completion of the study, for 21 of the 34 subjects (64 per cent) current drug therapy could be reduced or terminated. Thirteen of those did not require further drug therapy.
How Does It Work?
Why does the SDA- and ETA-rich oil of Perna canaliculus so remarkably outperform other omega-3s? The anti-inflammatory powers of all omega-3 fatty acids are grounded in biochemistry: the omega-3s' ability to bind up key enzymes involved in making "bad" eicosanoids. And as studies show, ETA, and SDA working through it, more potently prevent the formation of both types of "bad" eicosanoids: series-2 prostanoids and series-4 leukotrienes. Mechanisms are believed to include:
A stronger ability to tie up delta-5 desaturase, the enzyme that forms arachidonic acid.
Indirectly increasing the production of the "good" eicosanoids from DGLA.
ETA's close chemical resemblance to arachidonic acid, leading to stronger tying up of the LOX enzyme.
In addition to these advantages, SDA and ETA share anti-inflammatory mechanisms that are common to all omega-3 fatty acids. Thus, ETA and SDA are natural COX-2 inhibitors. Remarkably, omega-3s accomplish this feat not only because their natural metabolites bind up COX-2, but also by actually working at the gene level to reduce the production of COX-2 from the DNA code. And SDA/ETA block the formation of inflammatory cytokines (immune system messenger chemicals) such as tumor necrosis factor alpha (TNF-alpha) and interleukin-1 (IL-1). Revolutionary new painkillers - such as etanercept (Enbrel) are so effective because they target TNF-alpha.
ETA/SDA-based omega-3 supplements are an orthomolecular revolution, providing powerful support against inflammation in ways that other natural supplements can't match. The biochemistry explains the results seen in animal studies and clinical trials. But only you can experience them ... for yourself.
Eicosanoids are messengers that cells use to communicate with one another, coordinating their activities. Some ("bad") eicosanoids promote inflammation, while other ("good") eicosanoids have potent anti-inflammatory functions. Thus, the body's inflammatory response rests in large part on the balance of "good" and "bad" eicosanoids produced by your cells when they hear the immune system's inflammatory call.
"Bad" eicosanoids are made from an omega-6 fatty acid called arachidonic acid. Most drug approaches to inflammation, from aspirin and the older NSAIDs (Non-Steroidal Anti-Inflammatory Drugs, like ibuprofen) to the new "COX-2 inhibitor" drugs, like celecoxib [Celebrex] and rofecoxib [Vioxx]), work by inhibiting the formation of the series-2 prostanoid group of "bad" eicosanoids. Prostanoids are formed from arachidonic acid by an enzyme called cyclooxygenase, or COX. (AA).
But while these drugs certainly provide symptomatic relief in the short term, COX-2 inhibitors can actually accelerate the underlying inflammatory disease in the long term, by diverting arachidonic acid into another, slower-acting, and ultimately more destructive pathway: the lipoxygenase (LOX) enzyme pathway, which produces the ravaging series-4 leukotrienes. Leukotrienes are the eicosanoids released by immune cells involved in the body's inflammatory responses, and are more responsible for the long-term consequences of inflammation, which can result when a deranged immune system attacks the very body that it was designed to defend.
Therefore, blocking the COX pathway alone results in an imbalance - an imbalance that ultimately trades short-term gain for long-term pain. What people suffering with autoimmune disorders most need is a "dual pathway inhibitor:" a molecule which will shut down COX-2 and LOX alike, preventing the formation of all "bad" eicosanoids.
Transnational pharmaceutical giants are racing to create such drugs. But Nature is already waiting for them at the finish line, with two rare omega-3 fatty acids.
Introducing ETA and SDA
Eicosatetraenoic acid (ETA) and its raw material stearidonic acid (SDA), are omega-3 fatty acids you probably haven't heard much about. Because ETA and SDA are so rare in food sources, there's been little study of their role in the effects of diet on chronic disease (unlike eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which are commonly found in fatty fish and in regular fish-oil supplements).
While ETA is very rare in the normal Western diet, it is found in significant amounts in the fatty acids of the green-lipped mussel (Perna canaliculus). Many early studies in humans and animals found that crude extracts of Perna were effective in reducing inflammation, and in relieving the symptoms of rheumatoid and osteoarthritis - but other studies found no effect.
The reason, as later studies confirmed, was that the anti-inflammatory properties of the green-lipped mussel were due to their content of SDA and ETA. Most green-lipped mussel supplements are not stable fatty acid extracts, but are crude concentrates or are based on mucopolysaccharides. When seven commercially-available green mussel products were put to the test by comparing them with a stable fatty extract rich in ETA and SDA, the fatty acid extract revealed strong anti-inflammatory powers, while the other extracts were found to vary wildly in strength. Great variations were even revealed in different batches of the same product.
More tellingly, when the inflammation-fighting powers of a stable ETA- and SDA-rich extract were compared with crude P. canaliculus extracts whose fatty acid content had been deliberately removed, the fatty acid extract of the mussel exhibited potent anti-inflammatory effects, while the ETA-depleted preparation was found to be completely ineffective.
ETA and SDA Top the Omega-3s
Two direct comparison studies have been performed in animals to compare the anti-inflammatory effects of the ETA- and SDA-rich oil of P. canaliculus against those of salmon, cod liver, flaxseed, and two mixed fish oils. These studies clearly show that the ETA- and SDA-rich fatty acid extract of P. canaliculus is far superior to other omega-3 sources at quenching the fires of inflammation, giving more potent anti-inflammatory benefits at significantly lower doses.
Using the series of tests discussed above, ETA/SDA supplementation lowered arthritis scores by 4213% to 7515%, versus 0 to 31% using conventional omega-3 sources. Likewise, rear paw swelling was reduced by 96-98% by the ETA/SDA-rich oil, while swelling was only lowered by 7 to 38% with common omega-3s! These results are all the more remarkable because the dose of ETA/SDA-rich P. canaliculus oil was only about 1% of that used for the standard omega-3 oils.
Another recent study tested the effects of these novel fatty acids in a rat model of arthritis. After 15 days of administering omega-3 fatty acid extracts from P. canaliculus, rear paw swelling was significantly reduced by 34% and fore paw inflammation by 60%. Deterioration in total body condition was reduced by 52% compared to controls. The extract also decreased inflammatory response in the spleen, and it had a 35-70% inhibition of leukotriene metabolites. Serum levels of the inflammatory biomarker ceruloplasmin were reduced compared to control mice, indicating a less severe disease state. Interestingly, the fatty acids had comparable potency to the known anti-inflammatory agent piroxicam. The fatty acid extract had no adverse side effects. These results suggest a potential benefit not only in rheumatoid arthritis, but also in other inflammatory diseases such as psoriasis, asthma and cardiovascular disease.
A New Human Trial
In a new randomized, double-blind, controlled trial involving rheumatoid and osteoarthritis sufferers, significant improvements were reported in morning stiffness and measures of joint functionality during the double-blinded phase among rheumatoid arthritis sufferers taking the SDA/ETA-rich oil; further, night pain was "much improved" in 40% of subjects, and vanished in an additional 26.7%. Improvements were also seen in some patients' grip strength and overall visual-scale pain scores, but these results were not found statistically meaningful. Assessment by doctors and patients concluded that 73% of the persons with rheumatoid arthritis had experienced a good response - including 20% who became completely symptom-free by the end of the double-blind phase. The results were similar in the osteoarthritis victims.
Similar results have been reported in an unpublished pilot trial and in case reports. A double-blind, placebo-controlled trial vouches for the benefits of an SDA- and ETA-rich fatty acid supplement in bronchial asthma, and testimonial accounts and animal studies suggest benefits in premenstrual syndrome as well.
An Impressive Track Record
The accumulation of clinical and other scientific evidence pertaining to the efficacy and safety of ETA/SDA-rich oil has been growing steadily. The following is a partial summary of such studies:
1.Whitehouse Study 1. Anti-inflammatory activity of Lyprinol. Inflammapharmacology. 1997. Lyprinol was compared with dried mussel powder, residue mussel powder, Aspirin, Ibuprofen and Naproxen using the Wister rat protocol. Lyprinol was shown to be far superior as an anti-inflammatory.
2.Whitehouse Study 2. OTC oral remedies for arthritis. Lyprinol was compared to a multitude of over-the-counter products using the Wister rat protocol and was again shown to be a potent natural anti-inflammatory.
3.Sheila Gibson Study - Treatment of arthritis with Lyprinol. Complementary Therapies in Medicine (1998). This trial involved 60 patients, 30 osteoarthritis patients and 30 rheumatoid arthritis patients, during a period of three months. Lyprinol was compared to green-lipped mussel powder and was shown to outperform green-lipped mussel powder quite significantly.
4.Niels Hertz Study - Pilot study 13 patients 1998. This small pilot trial was conducted on 13 patients who had osteoarthritis. Within three to four months 12 of the 13 patients reported a 50 per cent reduction in arthritisrelated pain.
5.The effect of marine oils on markers of thrombosis in the blood of healthy females. Steve Hooper - October 1998. This trial involved 10 female subjects who took two different omega-3 products. One was Lyprinol and the other was a fish oil called Fishaphos. Both products showed no significant effect on any of the antithrombotic parameters measured.
6.Marine lipids: overview, new insights and lipids composition of Lyprinol. Andrew J. Sinclair, Karen J. Murphy and Li - Department of Food Science, RMIT University. This paper outlines the differences between the composition of Lyprinol compared with other oils that contain omega-3s.
7.Shiela L. M. Gibson - The effect of a lipid extract of the New Zealand greenlipped mussel in three cases of arthritis. The Journal of Alternative and Complementary Medicine, volume 6, number 4, 2000. In this trial, three cases of rheumatoid arthritis were looked at and treated with Lyprinol. In all three cases, the patients reported reduced pain, reduced stiffness and swelling, along with improved grip strength.
8.Chris D. Meletis, N. D. - Natural relief for inflammation of sprains, strains and arthritis. Alternative and Complementary Therapies - June 2000. This small comparison study outlined that Lyprinol with a dosage of 100mg twice daily is very effective in the management of sprains and strains.
9.Allergies and Immunologies no. 7 - September 2000 G. M. Halpern A. N. Naykhin, R. Borland, L. G. Rudenko (abstract) Lyprinol - a new modulator of human immune response to viral antigen. This report establishes the safety and effectiveness of Lyprinol by referring to many of the clinical trials that have been performed on Lyprinol.
10.A. N. Naykhin, R. Borland, G. G. Rudenko (paper) - Immunomodulating effect of Lyprinol in humans vaccinated with live influenza vaccine. This clinical trial indicated that Lyprinol possessed rather powerful immunomodulating properties (likely to have prolonged action) by enhancement of specific systemic and partly local and cellular immunity stimulation.
11.Dr M. W. Whitehouse et al (1997) Inflammopharmacology, 5.237-246 (Proceedings of ASCEPT) - The marine oil Lyprinol is a substrate for the 5-lipoxygenase enzyme in porcine neutrophils. - Steriod-sparing action of Lyprinol, a lipid fraction from the New Zealand greenlipped mussel.
12.English version of the Korean: Multicentre clinical trial of Lyprinol - published in 'The Newest Medical Journal (Korea) 2002 5.6 ISSN 0529-3804 (pages 27-33)'. This study was conducted in Korea on 54 patients who suffered from osteoarthritis. Eighty per cent displayed significant pain relief and joint mobility after eight weeks.
13.A. Emelyanov, G. Fedoseev, O. Krasnoschekova, A. Abulimity, T. Trendeleva, P. J. Barnes - Treatment of asthma with lipid extract of New Zealand green-lipped mussel: a randomized clinical trial. The Emelyanov study consisted of 40 mild, steroid naive asthmatics who received either an active or placebo dosage of 100mg per day. After 56 days, the patients in the active group showed a positive effect on clinical symptoms.
14.Gastroprotective and anti-inflammatory properties of green-lipped mussel (Perna canaliculus) preparation - By K. D. Rainsford and M. W. Whitehouse Arzneim-Forsch./Drug Res. 30(II), Nr.12 (1980). This small animal study indicated that this material reduced the gastric ulcerogenicity of several non-steroid anti-inflammatory drugs in rats and pigs.
15.Programme and abstracts annual scientific meeting, November 30 - December 3, 2003, Sydney. Australian Society of Clinical and Experimental Pharmacologists and Toxicologists, Vol. 10, 2003. Lyprinol effects on allergen-induced esinophil infiltration into the airways of sensitised guinea pigs in vivo.
16.Professor C. S. Lau. Volume number 6, N. 1/2004, pages. 17-31) Progress in Nutrition 2004. Treatment of knee osteoarthritis with Lyprinol, lipid extract of the green-lipped mussel, a double-blind placebo-controlled study. This study was conducted on 80 osteoarthritis sufferers and concluded that Lyprinol, a lipid extract of the green-lipped mussel, be considered a safe option in the treatment of osteoarthritis.
17.M. W. Whitehouse and D. E. Butters article in the Inflammopharmacology, volume 11, 4-6, pages 453-464 (2003) Combination anti-inflammatory therapy: synergism in rats of NSAIDs/corticosteroids with some herbal/animal products.
18.M. W. Whitehouse - Inflammopharmacology, Vol. 12, No. 3, pp. 223 - 227 (2004) Anti-TNF-alpha therapy for chronic inflammation: reconsidering pentoxifylline as an alternative to therapeutic protein drugs. Professor Whitehouse outlines in this paper that Lyprinol and pentoxifylline work extremely well together as a combination anti-inflammatory.
19.Joerg Gruenwald, Hans-Joachim Graubaum, Knuth Hansen, Barbara Grube - Advances In Natural Therapy, volume 21, number 3 May/June 2004 Efficacy and tolerability of a combination of Lyprinol and high concentrations of EPA and DHA in inflammatory rheumatoid disorders. This 12-week drug monitoring study evaluated the effects of Lyprinol omega-3 complex on 50 adult men and women suffering from inflammatory rheumatoid arthritis. Thirty-four of the 50 patients required medical treatment before and during the study. Upon completion of the study, for 21 of the 34 subjects (64 per cent) current drug therapy could be reduced or terminated. Thirteen of those did not require further drug therapy.
How Does It Work?
Why does the SDA- and ETA-rich oil of Perna canaliculus so remarkably outperform other omega-3s? The anti-inflammatory powers of all omega-3 fatty acids are grounded in biochemistry: the omega-3s' ability to bind up key enzymes involved in making "bad" eicosanoids. And as studies show, ETA, and SDA working through it, more potently prevent the formation of both types of "bad" eicosanoids: series-2 prostanoids and series-4 leukotrienes. Mechanisms are believed to include:
A stronger ability to tie up delta-5 desaturase, the enzyme that forms arachidonic acid.
Indirectly increasing the production of the "good" eicosanoids from DGLA.
ETA's close chemical resemblance to arachidonic acid, leading to stronger tying up of the LOX enzyme.
In addition to these advantages, SDA and ETA share anti-inflammatory mechanisms that are common to all omega-3 fatty acids. Thus, ETA and SDA are natural COX-2 inhibitors. Remarkably, omega-3s accomplish this feat not only because their natural metabolites bind up COX-2, but also by actually working at the gene level to reduce the production of COX-2 from the DNA code. And SDA/ETA block the formation of inflammatory cytokines (immune system messenger chemicals) such as tumor necrosis factor alpha (TNF-alpha) and interleukin-1 (IL-1). Revolutionary new painkillers - such as etanercept (Enbrel) are so effective because they target TNF-alpha.
ETA/SDA-based omega-3 supplements are an orthomolecular revolution, providing powerful support against inflammation in ways that other natural supplements can't match. The biochemistry explains the results seen in animal studies and clinical trials. But only you can experience them ... for yourself.
What People Are Saying:
- Reviews
- POST A NEW REVIEW
